Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029. With its portfolio of Cardiology and Peripheral Interventions products, Boston Scientific is set to benefit significantly from this upward trend.
The booming cardiovascular devices market, driven by aging demographics, minimally invasive procedures, and tech innovation, is propelling Boston Scientific's top-line growth, product leadership and stronger profitability. These tailwinds were clearly reflected in the company's robust first-quarter 2025 performance and raised full-year 2025 guidance.
In the past year, Boston Scientific's shares have skyrocketed roughly 31.8%, outpacing the broader Medical Product industry and the S&P 500 benchmark, which have improved about 8.9% and 11.9%, respectively. During this time, Boston Scientific has also outpaced key peers such as Abbott Laboratories ABT and Medtronic MDT. While Abbott, known for its structural heart, cardiac rhythm management, and diagnostics products, gained 24.2%, Medtronic, known for heart valves and coronary stents, advanced 5.1%.
BSX 1 Year Price Comparison
Major Tailwinds Driving BSX Stock
Strong Q1: In the first quarter of 2025, Boston Scientific's revenues were up 22.2% on an operational basis (at a constant exchange rate or CER). The Cardiovascular segment sales were up 26.2% year over year. Within this, Cardiology and Peripheral Interventions businesses' sales grew 31.2% and 7.4%, respectively, year over year. U.S. revenues rose 31%, driven by double-digit growth in most business units. Japan and China also delivered strong results, particularly in EP.
Boston Scientific reported adjusted earnings per share (EPS) of $0.75, up 34% year over year. The company's revenues and EPS rose due to exceptional top-line growth across key franchises, especially in EP and structural heart, combined with improved margin performance and disciplined cost management.
Cardiovascular Steals Spotlight: Boston Scientific's Electrophysiology business is rapidly expanding its global market share, with first-quarter 2025 organic growth surging 145%, positioning BSX as the number two player in the space. This growth is largely driven by strong commercial adoption of FARAPULSE, the company's flagship Pulsed Field Ablation ('PFA') system, which is gaining traction through global demand, new account expansions, and ongoing clinical studies like AVANT GUARD and Elevate PF.
Meanwhile, Boston Scientific's structural heart portfolio is also performing well, with WATCHMAN sales up 24% year over year, aided by DRG-enabled procedural growth. Next-gen versions — WATCHMAN FLX and FLX Pro — are accelerating adoption, while trials like CHAMPION-AF and OPTION A aim to expand the device's global market potential.
Boston Scientific's 2025 Outlook Looks Promising
For full-year 2025, Boston Scientific raised its organic revenue growth guidance to 12- 14% (from 10-12%) and now expects adjusted EPS of $2.87-$2.94, representing 14-17% year-over-year growth. Reported revenue growth is projected at 15-17%, including contributions from recent acquisitions like Axonics and Intera Oncology. Adjusted operating margin is expected to expand 50-75 basis points, driven by strong product mix, notably FARAPULSE and WATCHMAN, and cost efficiencies. Segmentally, Cardiology continues to lead growth, with Endoscopy and Neuromodulation expected to outperform markets and Urology affected modestly by supply constraints.
Estimates for BSX Heading North
The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. The bottom-line estimates have moved northward in the past 60 days.
BSX's Downsides
Boston Scientific continues to face a challenging business environment, thanks to industry-wide macroeconomic pressures, including geopolitical tensions, global supply-chain disruptions, and labor market instability. International conflicts and retaliatory trade actions have increased global risks, while volatile financial markets and fluctuating prices for goods and services are squeezing profitability.
Sustained macroeconomic pressures may make it more difficult for the company to manage operating expenses effectively. Tariffs are expected to have a $200 million impact in 2025, which, although planned to be offset through sales growth, cost controls and FX benefits, underscores the heightened complexity of the current environment.
BSX Stock Valuation
With a forward five-year price-to-earnings (P/E) of 33.31X, Boston Scientific's shares are trading at a premium compared with the industry average of 21.29X. It has a Value Score of D at present.
P/E Forward Twelve Months (F12M)
Meanwhile, MDT's five-year price-to-earnings (P/E) of 15.63X is lower than the industry average.
How to Play BSX Stock?
Considering Boston Scientific's strong operational performance, leadership in fast-growing cardiovascular segments like Electrophysiology and Structural Heart, and promising pipeline of developments, the company is clearly executing well on both growth and profitability fronts. With projected double-digit revenue and earnings growth, BSX is poised to continue delivering shareholder value, even amid a complex macroeconomic backdrop and tariff headwinds.
The stock has excelled both the industry and its peers, and its estimates are likely to continue to trend upward in the near term. Henceforth, the current BSX shareholders may find it prudent to stay invested.
Boston Scientific carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 minutes ago
- Globe and Mail
'Operational Friction': Warner Bros Discovery Stock (NASDAQ:WBD) Jumps as Some Worry About the Split's Impact
Entertainment giant Warner Bros. Discovery (WBD) recently made a move that was, seemingly, inevitable: to take its linear cable content and spin it off from its streaming video content and put the two packages into their own operations. And investors were over the moon about this, and remain so today. Not everyone is so certain this idea will work, though. But shareholders were definitely on board, and sent Warner shares up nearly 4% in Tuesday afternoon's trading. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Barclays analyst Kannan Venkateshwar, who has nearly a five-star rating on TipRanks, noted that the move may produce 'operational friction,' especially given how some of these operations may need to be restructured from the ground up to separate. Venkateshwar pointed out that Max is actually bundled with Warner's linear content, so separating the linear content from the streaming content would likely require those bundles to be reworked as well. Moreover, the separation also fails to address the matter of $37 billion in outstanding debt that Warner still carries. Warner is putting the linear stuff into the hands of Chief Financial Officer Gunnar Wiedenfels, who noted that 'global networks' would have most of Warner's debt. The streaming and studios business, meanwhile, would maintain a smaller, '…but not insignificant…' portion therein. And Then the Bondholders Saw the Bag They Were Holding One more problem emerged out of the Warner split: bondholders. Three years ago, Warner sold what was one of the biggest 'high-grade corporate bonds on record,' reports noted. Now, those who bought in are left with a disastrous choice. Warner is buying back up to 40% of those bonds, thanks to a $17.5 billion bridge loan. But no matter whether holding or selling, the bondholders now have a bigger problem. Part of the condition of selling, reports note, is the loss of 'key safeguards' on other Warner securities they might own. But those who keep the notes to keep those safeguards will find their position in the creditor line pushed back should that become an issue later on. Cooperation pacts, the reports note, will also be tougher to form, meaning that bondholders that actually keep their debt will have fewer protections overall. Is WBD Stock a Good Buy? Turning to Wall Street, analysts have a Moderate Buy consensus rating on WBD stock based on nine Buys and eight Holds assigned in the past three months, as indicated by the graphic below. After a 18.53% rally in its share price over the past year, the average WBD price target of $12.43 per share implies 25.3% upside potential. See more WBD analyst ratings Disclosure Disclaimer & Disclosure Report an Issue
Globe and Mail
10 minutes ago
- Globe and Mail
Why Rigetti Computing Stock Is Skyrocketing Today
Rigetti Computing (NASDAQ: RGTI) stock is roaring higher in Wednesday's trading thanks to multiple positive catalysts. The quantum computing specialist's share price was up 10.9% as of 3:30 p.m. ET. Shares had been up as much as 20.6% earlier in the daily session. Rigetti's valuation is getting a huge boost today after Nvidia CEO Jensen Huang made comments suggesting that quantum computing technologies could be ready to take off. The stock is also getting a lift from better-than-expected inflation data released by the Bureau of Labor Statistics (BLS) today. Nvidia's Jensen Huang suggests quantum computing could be ready to take off Nvidia kicked off its GTC Paris developers conference this morning, and CEO Jensen Huang had some promising things to say about the trajectory of quantum computing technologies. "Quantum computing is reaching an inflection point," Huang said in his keynote speech for the conference this morning. The CEO's comments kicked off another powerful rally for quantum computing stocks, and Rigetti's valuation has surged thanks to the catalyst. The latest inflation data looks like a bullish indicator for Rigetti stock The Bureau of Labor Statistics published May's consumer price index (CPI) inflation data this morning, and the results seem to bode well for Rigetti Computing stock. Core CPI, which is a measure for inflation that looks at prices for a combination of goods and excludes food and energy expenses, rose at a 2.8% annual rate last month. Core CPI inflation ticked up just 0.1% compared to April's figure. Meanwhile, economists had expected that annual inflation for core CPI would be up 2.9% and that monthly inflation would be up 0.2%. Core CPI came in cooler than expected, and this seemingly supports the notion that the Federal Reserve is seeing economic data that leaves the door open for an interest rate cut this year. If the Fed does deliver a rate cut, that would likely be a strong positive catalyst for Rigetti Computing and other speculative growth stocks. Should you invest $1,000 in Rigetti Computing right now? Before you buy stock in Rigetti Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rigetti Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor 's total average return is996% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
14 minutes ago
- Globe and Mail
Is Intel the Turnaround Stock of 2025 and a Buy Now?
Intel Corporation INTC stock plunged 70% post chip foundry venture, yet Lip-Bu Tan's appointment as new CEO and recent 10% stock rise hint at a potential turnaround. Is it a good buy now? Let's see. Intel May Rebound in 2025 for Four Key Reasons Both Intel and NVIDIA Corporation NVDA produce graphics processing units (GPUs) that are essential for modern computing, including machine learning and artificial intelligence (AI). However, NVIDIA's CUDA software and Blackwell chips are highly sought after by developers and customers. The superior products from NVIDIA have allowed the company to secure a substantial share in most major AI segments, including data centers (read more: Is NVIDIA's Rise in Value a Sign to Invest in NVDA Stock?). Of course, it's challenging for Intel to compete with NVIDIA, but the former has more room to grow with a market capitalization of under $100 billion compared to NVIDIA's $3 trillion plus. Moreover, Intel's affordable AI accelerators can rival NVIDIA's. Intel is spending billions of dollars on enhancing its AI capabilities and may enter the market with energy-efficient chips. In the last two years, Intel has spent over $50 billion on upgrading its chip-manufacturing facilities. Such staggering infrastructure costs have made investors nervous due to the unprofitable foundry business. Intel's foundry business continues to face tough competition from the likes of Taiwan Semiconductor Manufacturing Company Limited TSM, or TSMC, and Samsung. However, TSMC and Samsung located in Southeast Asia, have manufacturing centers in China. The ongoing trade tensions between the United States and China could disrupt their business. In contrast, Intel's chip-making hubs are primarily in the United States, allowing domestic semiconductor companies to send chip orders to these facilities and bypass trade restrictions. Despite losing the top semiconductor title, Intel generated revenues of $12.7 billion in the first quarter of 2025, outpacing arch-rival Advanced Micro Devices, Inc.'s AMD $7.4 billion. This serves as a clear indication that Intel is making strides in the semiconductor industry and is well-positioned for a comeback. Last but not least, Lip-Bu Tan's appointment as the CEO of Intel has been well-received by market pundits, as his stint in the semiconductor industry has been productive. Tan's initiatives to streamline operations, deliver a competitive AI platform, and spin-off assets would restore stability at Intel and help the company return to its past glory. Is Intel Stock Worth Buying Now? With Lip-Bu Tan leading Intel's foundry recovery and AI accelerators gaining ground among competitors through cost advantages, holding onto INTC stock seems judicious. Intel's business revival is becoming more probable, and brokers are showing optimism by increasing the short-term price target for INTC to $22.42 (up 9.5%) from $20.48. The highest target is $62, indicating a potential 202.7% upside. However, Intel's net profit margin is negative at 36.2%, while the Semiconductor - General industries have a margin of 49.5%, suggesting financial instability due to expenses surpassing revenues. Therefore, new entrants, for now, should wait for improved financials before considering INTC stock. Intel has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report
